skip to Main Content
info@nektrtechnologies.com

Our R&D Pipeline

A3IS has proven to kill ESKAPE as well as critical and high priority WHO specified pathogens and established biofilms with no resistance observed.

A3IS is a viable alternative to increasingly ineffective antibiotics.

Core Developments – Multi Drug Resistant Pathogens

A3IS has proven to kill all ESKAPE as well as critical and high priority WHO specified pathogens. A3IS is highly effective at removing established biofilms and is a viable alternative to increasingly ineffective antibiotics

The discovery of antibiotics has long been regarded as one of the most significant medical achievements saving millions of lives and enabling the performance of difficult medical procedures. The emergence and spread of global antimicrobial resistance poses a serious risk to public health and the provision of effective healthcare.

A3IS has demonstrated exceptional anti-microbial efficacy against the most dangerous pathogenic organisms worldwide with no resistance observed.

Image

Critical & High Priority Pathogens

Demonstrated Drug Resistance against the following Antibiotics

MIC % A3IS

Image:

b1

Critical & High Priority Pothogens:

Escherichia Coli

Demonstrated Drug Resistance against the following Antibiotics:

Carbapenem, 3rd Gen. Cephalosporin, Quinolone, Penicillin, Macrolide, Chloramphenicol, Glycopeptide, Aminoglycoside

Demonstrated ZOI Effectiveness with A3IS:

0.16

Image:

b2

Critical & High Priority Pothogens:

Pseudomonas Aeruginosa

Demonstrated Drug Resistance against the following Antibiotics:

Carbapenem, 3ed Gen. Cephalosporin, Penicillin, Macrolide, Glycopeptide, Aminoglycoside

Demonstrated ZOI Effectiveness with A3IS:

0.04

Image:

b3

Critical & High Priority Pothogens:

Staphylococcus Aureus

Demonstrated Drug Resistance against the following Antibiotics:

Vancomycin, Methicilin, Penicillin, Macrolie, Chloramphenicol, Monobactam, Polymyxin

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

b5

Critical & High Priority Pothogens:

Klebsiella Pneumonia

Demonstrated Drug Resistance against the following Antibiotics:

Penicillin, Macrolie, Chloramphenicol, Aminoglycoside

Demonstrated ZOI Effectiveness with A3IS:

0.08

Image:

b6

Critical & High Priority Pothogens:

Acinetobacter Baumannii

Demonstrated Drug Resistance against the following Antibiotics:

Glycopeptide, Penicillin

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

b7

Critical & High Priority Pothogens:

Neisseria Gonorrhoeae

Demonstrated Drug Resistance against the following Antibiotics:

Polymyxin

Demonstrated ZOI Effectiveness with A3IS:

0.01

Image:

b8

Critical & High Priority Pothogens:

Cutibacterium Acnes

Demonstrated Drug Resistance against the following Antibiotics:

Clindamycin

Demonstrated ZOI Effectiveness with A3IS:

0.08

Image:

b9

Critical & High Priority Pothogens:

Enterococcus Faecalis

Demonstrated Drug Resistance against the following Antibiotics:

3ed Gen. Cephalosporin, Polymyxin, Chloramphenicol, Aminoglycoside

Demonstrated ZOI Effectiveness with A3IS:

0.04

Image:

b10

Critical & High Priority Pothogens:

Beta Haemolytic Streptococci Group A

Demonstrated Drug Resistance against the following Antibiotics:

No tested

Demonstrated ZOI Effectiveness with A3IS:

2.5

Core Developments – Antifungal Efficacy

Image

Common Fungal Pathogens

MIC % A3IS

Image:

altenaria

Critical & High Priority Pothogens:

Altenaria

Demonstrated ZOI Effectiveness with A3IS:

0.08

Image:

aspergillus

Critical & High Priority Pothogens:

Aspergillus spp.

Demonstrated ZOI Effectiveness with A3IS:

0.04

Image:

Blastomyces

Critical & High Priority Pothogens:

Blastomyces dermatitidis

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

fungus 2

Critical & High Priority Pothogens:

Candida auris

Demonstrated ZOI Effectiveness with A3IS:

0.08

Image:

candida

Critical & High Priority Pothogens:

Candida spp.

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

coccidioides

Critical & High Priority Pothogens:

Coccidioides spp.

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

cryptococcus neofomrans

Critical & High Priority Pothogens:

Cryptococcus neofomrans

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

fungus 3

Critical & High Priority Pothogens:

Curvularia

Demonstrated ZOI Effectiveness with A3IS:

0.15

Image:

exophialia

Critical & High Priority Pothogens:

Exophialia

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

exserohilum

Critical & High Priority Pothogens:

Exserohilum

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

Fusarium

Critical & High Priority Pothogens:

Fusarium spp.

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

pneomocystis

Critical & High Priority Pothogens:

Pneumocystis spp.

Demonstrated ZOI Effectiveness with A3IS:

0.01

Image:

rhizopus

Critical & High Priority Pothogens:

Rhizopus arrhizus

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

fungus 3

Critical & High Priority Pothogens:

Scedosporium spp.

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

fungus 2

Critical & High Priority Pothogens:

Trichophyton Interdigitale

Demonstrated ZOI Effectiveness with A3IS:

0.02

Image:

t rubrium

Critical & High Priority Pothogens:

Trichophyton rubrum

Demonstrated ZOI Effectiveness with A3IS:

0.02

National Institute of Allergy and Infectious Diseases

Further testing against the outstanding WHO pathogens will be carried out by the US Federal Government National Institute of Allergy and Infectious Diseases (NIAID).

A3IS and Antibiotic Area of Inhibition Test Examples

Figure 3 A3IS is highly effective against the critical priority pathogen carbapenem resistant P. aeruginosa. Note that the AOI achieved by meropenem was below the EUCAST specified sensitivity threshold of 255mm2. The tested pathogen can therefore be classed as carbapenem resistant.

A3IS and Antibiotic Area of Inhibition Test Examples

Figure 4 A3IS is highly effective against the high priority pathogen vancomycin and methicillin resistant S. aureus (MRSA).

Anti-Biofilm Testing

Bridge PTS (San Antonio, TX) carried out a study investigating A3IS’ efficacy against established biofilms. A complex biofilm containing S. aureus, P. aeruginosa and E. coli was cultured utilising a Modified Robbins Device (MRD). The test materials were added to the established biofilm and incubated (37°C) for 4 hours. Colony Forming Units (CFUs) were then established.

Skin Tek

With its antimicrobial and stimulatory properties, A3IS shows great promise as a potential alternative to antibiotics for the treatment of infected skin lacerations, chronic wounds and dermatological conditions.

1

Highly Potent Antimicrobial and Anti-Biofilm Effects

The sustained release of H2O2 facilitates the Broad-Spectrum Antimicrobial and Anti-Biofilm Activity. It provides sterilization and stimulates vascular endothelial growth factor production.

2

Natural Barrier

The high viscosity of A3IS forms a barrier between the wound and the external environment, protecting against bacteria and providing hydration. The high sugar content also provides an additional source of glucose for proliferating cellular components such.

Wound Debridement

The sustained release of H2O2 supports the removal of necrotic tissue to promote the wound healing process. Not only does dead skin inhibit the development of healthy new tissue, but it makes the affected area more susceptible to infection.

4

High Osmolarity

The high concentration of sugars and other solutes creates a strong osmotic gradient which causes fluid flow through the subdermal tissue flushing bacteria, debris, slough, and necrotic tissue out of the wound, and carrying nutrients.

5

Low pH Levels

A3IS’ lower pH reduces protease activity, increases oxygen release from haemoglobin, and stimulates the activity of macrophages and fibroblasts during the wound healing process.

6

Hormetic Effect

A3IS has the capacity to initiate the Hormesis Effect, a biological phenomenon whereby a beneficial effect results from exposure to low doses of an agent that is toxic when given at higher doses. A3IS exposes skin to a low dose of H2O2 which causes.

Skin Tek

The skin is the largest organ of the human body with many physiological and immunological functions. Wound infections and chronic wound management pose a significant challenge to health care systems globally, especially considering the timely threat of multi-drug resistant pathogens. A person’s skin also defines one’s physical appearance. It is therefore not surprising that significant correlations between visible dermatological skin conditions, psycho social functioning as well as quality of life exist.

With its antimicrobial and stimulatory properties, A3IS shows great promise as a potential alternative to antibiotics for the treatment of infected skin lacerations, chronic wounds and dermatological conditions.

Contact Us

Do you have questions about Nektr or our technology? Connect with us using the details below or get in touch by filling out the form We would be happy to answer your questions!

Nektr Technologies,
Finisklin Business & Technology Park,
Sligo, Ireland, F91 HF66
+353 71 91 43861
info@nektrtechnologies.com
Send us a message




    Back To Top